Table 1 Baseline characteristics of patients with prevalent chronic obstructive pulmonary disease
Population 1 | Population 2 | |
|---|---|---|
104,439 | 54,689 | |
Male | 57,030 (54.6) | 30,065 (55.0) |
Age (years) | ||
40–49 | 4638 (4.4) | 3015 (5.5) |
50–59 | 17,527 (16.8) | 10,185 (18.6) |
60–69 | 33,079 (31.7) | 17,606 (32.2) |
70–79 | 35,869 (34.3) | 17,867 (32.7) |
≥ 80 | 13,326 (12.8) | 6016 (11.0) |
COPD medication | ||
LAMA | 12,266 (11.7) | 6277 (11.5) |
LABA | 3187 (3.1) | 1650 (3.0) |
LAMA/LABA | 2869 (2.7) | 1241 (2.3) |
LABA/ICS | 18,222 (17.4) | 9259 (16.9) |
LAMA/LABA/ICS | 4211 (4.0) | 2186 (4.0) |
Methylxanthines | 49,002 (46.9) | 25,363 (46.4) |
Others | 36,920 (35.4) | 19,048 (34.8) |
Comorbidity | ||
Asthma | 80,909 (77.5) | 41,482 (75.9) |
Hyperlipidemia | 72,633 (69.5) | 35,569 (65.0) |
Hypertension | 64,886 (62.1) | 31,419 (57.5) |
Diabetes | 51,598 (49.4) | 24,624 (45.0) |
Cerebrovascular disease | 23,984 (23.0) | 10,634 (19.4) |
Cancer | 20,228 (19.4) | 9584 (17.5) |
Congestive heart failure | 18,720 (17.9) | 7957 (14.5) |
Arrhythmia | 12,669 (12.1) | 5828 (10.7) |
Bronchiectasis | 12,513 (12.0) | 6141 (11.2) |
Renal disease | 4506 (4.3) | 1915 (3.5) |
Valvular disease | 1998 (1.9) | 860 (1.6) |
Environmental lung disease | 1164 (1.1) | 541 (1.0) |
Liver disease | 896 (0.9) | 386 (0.7) |
Quintiles for estimated household income | ||
1 | 11,247 (10.8) | 4775 (8.7) |
2 | 17,367 (16.6) | 9148 (16.7) |
3 | 16,227 (15.5) | 8731 (16.0) |
4 | 23,034 (22.1) | 12,450 (22.8) |
5 | 36,564 (35.0) | 19,585 (35.8) |